OncologyBowel cancer immunotherapy pair keeps 3 in 4 alive at five years
Final CheckMate 8HW data show nivolumab plus ipilimumab left 77% of people with MSI-high metastatic bowel cancer alive at five years, against 46% on chemotherapy.
24 October 2026